Pharm-Olam Blog

Pharm-Olam is a mid-sized, global CRO that provides clinical research solutions for rare diseases, oncology, hematology, autoimmune conditions, allergies, and infectious diseases. Our organization was hired to support a Phase I, first-in-human study of a programmed cell death receptor (PD-1) inhibitor monoclonal antibody (mAb) drug treatment for solid tumor malignancies. The research is in its final stages. Pharm-Olam is proud to have supported this critical research, the patients and the sponsor involved.